Context Therapeutics Inc. (CNTX) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-02-23

Key Insights

The reporting person, Martin A. Lehr, acquired 815,000 stock options in Context Therapeutics Inc. (CNTX) on February 19, 2026, indicating strong management confidence in the company's future prospects.
The stock options have a strike price of $2.32 and a 10-year expiration date, suggesting a long-term investment horizon for the reporting person.
The options vest over a 4-year period, aligning the reporting person's incentives with long-term shareholder value creation.

Want the newest filings?

This analysis covers the filing from 2026-02-23. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-02-23

Karen Deborah Chagin, the Chief Medical Officer of Context Therapeutics Inc. (CNTX), has been granted a stock option to acquire 290,000 shares of the company's common stock, vesting over a four-year period.
The exercise price of the stock option is $2.32 per share, which could potentially provide Chagin with a financial incentive to drive the company's growth and performance.
As an officer of the company, Chagin's stock option acquisition could be seen as a positive signal of management's confidence in the company's future prospects.

Filed: 2026-02-23

Jennifer Lynn Minai-Azary, the Chief Financial Officer of Context Therapeutics Inc. (CNTX), has been granted a stock option of 275,000 shares, vesting over a four-year period.
This insider transaction indicates the company's commitment to incentivizing its leadership team and aligning their interests with those of shareholders.
The timing of this grant, close to the company's financial reporting period, suggests it may be part of the company's regular compensation practices.

Filed: 2026-02-23

Alex C. Levit, the Chief Legal Officer and Corporate Secretary of Context Therapeutics Inc., has received a stock option grant of 270,000 shares with an exercise price of $2.32.
The option vests over a four-year period, with 25% vesting on February 19, 2027, and the remaining balance vesting in equal monthly installments over the following three years.
This stock option grant suggests that Levit is incentivized to remain with the company and contribute to its long-term success.

Other reports for Context Therapeutics Inc.

Quarterly Report Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.